Oaktree Capital Management is to invest $150 million in Czech firm Draslovka, “providing preferred equity capital to support the company’s growth strategy”. This follows multiple recent acquisitions by Draslovksa, a family-owned specialist in CN-based chemicals, including next generation fumigants and biocides.